Kieren A Marr

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies
    Kieren A Marr
    Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon 97239, USA
    Curr Opin Infect Dis 21:409-14. 2008
  2. ncbi Fungal infections in hematopoietic stem cell transplant recipients
    Kieren A Marr
    Oregon Health and Sciences University, Portland, Oregon 97239, USA
    Med Mycol 46:293-302. 2008
  3. ncbi Factors associated with mortality in transplant patients with invasive aspergillosis
    John W Baddley
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, AL 35294 0006, USA
    Clin Infect Dis 50:1559-67. 2010
  4. ncbi Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)
    Peter G Pappas
    Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham Medical Center, Birmingham, Alabama 35294 0006, USA
    Clin Infect Dis 50:1101-11. 2010
  5. ncbi Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections
    David L Horn
    Division of Infectious Diseases, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA
    Diagn Microbiol Infect Dis 59:407-14. 2007
  6. ncbi Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network
    John W Baddley
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294 0006, USA
    J Clin Microbiol 47:3271-5. 2009
  7. ncbi Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients
    Penelope D Barnes
    Division of Infectious Diseases, Oregon Health and Science University, Portland, OR 97239, USA
    Br J Haematol 139:519-31. 2007
  8. ncbi Amphotericin B: time for a new "gold standard"
    Luis Ostrosky-Zeichner
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, TX, USA
    Clin Infect Dis 37:415-25. 2003
  9. ncbi Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole
    Alexander Imhof
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Clin Infect Dis 39:743-6. 2004
  10. ncbi Combination antifungal therapy for invasive aspergillosis
    Kieren A Marr
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Clin Infect Dis 39:797-802. 2004

Research Grants

  1. Antifungal Drug Resistance in Aspergillus
    Kieren Marr; Fiscal Year: 2004
  2. Immune reconstitution to Aspergillus
    Kieren Marr; Fiscal Year: 2007
  3. BioRad Galactomannan EIA for Diagnosis of Aspergillosis
    Kieren Marr; Fiscal Year: 2007
  4. Inflammatory Responses to Aspergillus Fumigatus
    Kieren Marr; Fiscal Year: 2007
  5. Genetic Diversity of A. fumigatus
    Kieren Marr; Fiscal Year: 2007

Detail Information

Publications65

  1. ncbi Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies
    Kieren A Marr
    Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon 97239, USA
    Curr Opin Infect Dis 21:409-14. 2008
    ..Availability of new antifungal drugs has led to creative attempts to prevent infections caused by both yeasts and molds with new antifungal prophylaxis strategies; these studies will be reviewed...
  2. ncbi Fungal infections in hematopoietic stem cell transplant recipients
    Kieren A Marr
    Oregon Health and Sciences University, Portland, Oregon 97239, USA
    Med Mycol 46:293-302. 2008
    ..This review discusses invasive fungal infections in hematopoietic stem cell transplant recipients, with a focus on the host and the two most common infections, candidiasis and those caused by moulds...
  3. ncbi Factors associated with mortality in transplant patients with invasive aspergillosis
    John W Baddley
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, AL 35294 0006, USA
    Clin Infect Dis 50:1559-67. 2010
    ..The purpose of this study was to evaluate factors associated with mortality in transplant patients with IA...
  4. ncbi Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)
    Peter G Pappas
    Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham Medical Center, Birmingham, Alabama 35294 0006, USA
    Clin Infect Dis 50:1101-11. 2010
    ..Invasive fungal infections (IFIs) are a major cause of morbidity and mortality among organ transplant recipients. Multicenter prospective surveillance data to determine disease burden and secular trends are lacking...
  5. ncbi Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections
    David L Horn
    Division of Infectious Diseases, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA
    Diagn Microbiol Infect Dis 59:407-14. 2007
    ..As enrollment continues, additional data will be analyzed and published, which will provide valuable information concerning the epidemiology, therapy, and outcomes of IFIs...
  6. ncbi Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network
    John W Baddley
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294 0006, USA
    J Clin Microbiol 47:3271-5. 2009
    ..61; P = 0.065). Significant relationships of in vitro MIC to all-cause mortality at 6 and 12 weeks for VOR or AMB were not found...
  7. ncbi Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients
    Penelope D Barnes
    Division of Infectious Diseases, Oregon Health and Science University, Portland, OR 97239, USA
    Br J Haematol 139:519-31. 2007
    ..HSCT recipients often have multiple co-morbidities, and understanding the current outcomes and prognostic variables is therefore important for overall management. This paper reviews historical trends and current data...
  8. ncbi Amphotericin B: time for a new "gold standard"
    Luis Ostrosky-Zeichner
    Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, TX, USA
    Clin Infect Dis 37:415-25. 2003
    ..Given their superior safety profiles, these preparations can now be considered suitable replacements for AmBD for primary therapy for many invasive fungal infections in clinical practice and research...
  9. ncbi Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole
    Alexander Imhof
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Clin Infect Dis 39:743-6. 2004
    ..Minimal inhibitory concentrations were > or =1 microg/mL for all available isolates. Yeasts and molds with decreased susceptibility to voriconazole may cause invasive infection in patients treated successfully for aspergillosis...
  10. ncbi Combination antifungal therapy for invasive aspergillosis
    Kieren A Marr
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Clin Infect Dis 39:797-802. 2004
    ..The results of in vitro studies and animal models suggest that combination therapy with azoles and echinocandins may have additive activity against Aspergillus species...
  11. ncbi Issues in the design of the fluconazole prophylaxis trials in patients undergoing hematopoietic stem cell transplantation
    Kieren A Marr
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, USA
    Clin Infect Dis 39:S170-5. 2004
    ..An understanding of design issues can help explain current controversies and can assist in development of future prophylaxis studies...
  12. ncbi Determination of antifungal drug susceptibilities of Aspergillus species by a fluorescence-based microplate assay
    S Arunmozhi Balajee
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N D3 100, Seattle, WA 98109, USA
    J Antimicrob Chemother 55:102-5. 2005
    ..We have investigated the use of a viability dye, chloromethylfluorescein di-acetate (CMFDA), for antifungal susceptibility testing in a fluorescence microplate (FM) assay format...
  13. ncbi Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid
    Benjamin Musher
    University of Washington, Seattle, WA, USA
    J Clin Microbiol 42:5517-22. 2004
    ..GM EIA and qPCR assay add to the sensitivity of BAL for diagnosing IPA in high-risk patients, with excellent specificity. Adjunctive use of these tests may reduce dependence on invasive diagnostic procedures...
  14. ncbi Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation
    Arlo Upton
    Clinical Research Division, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington, USA
    Biol Blood Marrow Transplant 13:760-4. 2007
    ..No difference in relapsed malignancy was apparent. These data support the hypothesis that fluconazole, when coadministered with CY, decreases CY-related toxicities by inhibiting cytochrome P450 2C9 metabolism...
  15. ncbi Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay
    Kieren A Marr
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Clin Infect Dis 40:1762-9. 2005
    ..Reported sensitivity of the galactomannan enzyme immunoassay as an early diagnostic test for invasive aspergillosis (IA) has been widely variable, ranging from 29% to 100% in earlier clinical studies...
  16. ncbi Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatus
    S Arunmozhi Balajee
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D3-100, Seattle, WA 98109, USA
    J Clin Microbiol 43:5996-9. 2005
    ..Accurate identification of these organisms may be clinically meaningful, given their potential differences in antifungal susceptibilities...
  17. ncbi Clinical significance of azole antifungal drug cross-resistance in Candida glabrata
    Anil A Panackal
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, 1100 Fairview Ave, D3-100, Seattle, WA 98109, USA
    J Clin Microbiol 44:1740-3. 2006
    ..Caution is advised when considering voriconazole therapy for C. glabrata candidemia that occurs in patients with extensive prior azole drug exposure...
  18. ncbi Aspergillus ustus infections among transplant recipients
    Anil A Panackal
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Emerg Infect Dis 12:403-8. 2006
    ..Based on the clustering of cases in space and time and molecular data, common-source acquisition of this unusual drug-resistant species is possible...
  19. ncbi Fusarium infection in hematopoietic stem cell transplant recipients
    Marcio Nucci
    University Hospital, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
    Clin Infect Dis 38:1237-42. 2004
    ..The actuarial survival was 13% (median, 13 days). Persistent neutropenia was the single prognostic factor for death identified by multivariate analysis...
  20. ncbi Differential role of MyD88 in macrophage-mediated responses to opportunistic fungal pathogens
    Kieren A Marr
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, 98109, USA
    Infect Immun 71:5280-6. 2003
    ..albicans, but not A. fumigatus. The differential role of MyD88 may represent one mechanism by which macrophages regulate innate responses specific to different pathogenic fungi...
  21. ncbi Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
    Raoul Herbrecht
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
    N Engl J Med 347:408-15. 2002
    ..Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to compare voriconazole with amphotericin B for primary therapy of invasive aspergillosis...
  22. ncbi Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors
    Kieren A Marr
    Fred Hutchinson Cancer Research Center Programs in Infectious Diseases and Long term Follow up, Seattle, WA 98109, USA
    Blood 100:4358-66. 2002
    ....
  23. ncbi Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture?
    Christian Junghanss
    Department of Medicine, University of Rostock, School of Medicine, Rostock, Germany
    Curr Opin Infect Dis 15:347-53. 2002
    ..Further studies are necessary to define appropriate preventative strategies, and to determine whether patients with ongoing infections might benefit from nonmyeloablative hematopoietic stem cell transplantation...
  24. ncbi Long-term care after hematopoietic-cell transplantation in adults
    Michael Boeckh
    N Engl J Med 347:1625-6; author reply 1625-6. 2002
  25. ncbi Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice
    Justina Y Ju
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 46:1240-5. 2002
    ..This murine model provided evidence of the efficacy of amphotericin B and caspofungin but not of fluconazole against C. glabrata infection...
  26. ncbi Aspergillosis. Pathogenesis, clinical manifestations, and therapy
    Kieren A Marr
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue, N D3 100, Seattle, WA 98109, USA
    Infect Dis Clin North Am 16:875-94, vi. 2002
    ..This article focuses on the pathogenesis and clinical manifestations of diseases caused by Aspergillus species, with more detailed discussion on therapy of the most morbid manifestation, invasive aspergillosis...
  27. ncbi Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning
    Takahiro Fukuda
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 102:827-33. 2003
    ..More effective strategies are needed to prevent invasive mold infections, which currently account for a notable proportion of nonrelapse mortality after nonmyeloablative allogeneic HCT...
  28. ncbi Voriconazole treatment for less-common, emerging, or refractory fungal infections
    John R Perfect
    Department of Medicine and Microbiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Infect Dis 36:1122-31. 2003
    ..Voriconazole is an effective and well-tolerated treatment for refractory or less-common invasive fungal infections...
  29. ncbi New approaches to invasive fungal infections
    Kieren A Marr
    Fred Hutchinson Cancer Research Center, University of Washington, Seatle, WA 98109, USA
    Curr Opin Hematol 10:445-50. 2003
    ..This review will describe these most recent developments with the goal of evaluating new approaches to prevent, diagnose, and treat invasive fungal infections...
  30. ncbi Empirical antifungal therapy--new options, new tradeoffs
    Kieren A Marr
    N Engl J Med 346:278-80. 2002
  31. ncbi Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients
    Kieren A Marr
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, WA, USA
    Clin Infect Dis 34:909-17. 2002
    ....
  32. ncbi Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 14:799-806. 2008
    ..94 [1.0-3.8], P = .05), but not for overall mortality or NRM. We propose that intensified strategies to prevent infections should be implemented in MDS patients with preexisting neutropenia who undergo HSCT...
  33. ncbi Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality
    Arlo Upton
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109, USA
    Clin Infect Dis 44:531-40. 2007
    ..The aim of this study was to determine the probability of survival and prognostic factors associated with outcomes over a long period of time...
  34. ncbi Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C
    Ben de Pauw
    Department of Blood Transfusion Service and Transplant Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Infect Dis 46:1813-21. 2008
    ..Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies...
  35. ncbi Phenotypic and genotypic identification of human pathogenic aspergilli
    S Arunmozhi Balajee
    Centers for Disease Control and Prevention, Mycotic Diseases Branch, Atlanta, GA 30333, USA
    Future Microbiol 1:435-45. 2006
    ..This review focuses on current and future methods of identifying aspergilli, and implications regarding Aspergillus species/strain identification...
  36. ncbi Conidial viability assay for rapid susceptibility testing of Aspergillus species
    S Arunmozhi Balajee
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Clin Microbiol 40:2741-5. 2002
    ..e., NCCLS) method. The results of these studies illustrate a method by which AMB susceptibility can be rapidly and reproducibly determined by measuring conidial viability...
  37. ncbi Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation
    Pierre Yves Bochud
    Institute for Systems Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    N Engl J Med 359:1766-77. 2008
    ..We examined the role of TLR polymorphisms in conferring a risk of invasive aspergillosis among recipients of allogeneic hematopoietic-cell transplants...
  38. ncbi MyD88 signaling contributes to early pulmonary responses to Aspergillus fumigatus
    Camille Bretz
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Infect Immun 76:952-8. 2008
    ..Resolution of abnormalities within a 3-day window demonstrates the importance of redundant signaling pathways in mediating pulmonary inflammatory responses to fungi...
  39. ncbi Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America
    Thomas J Walsh
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Clin Infect Dis 46:327-60. 2008
  40. ncbi Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation
    Carol Garcia-Vidal
    Fred Hutchinson Cancer Research Center, USA
    Clin Infect Dis 47:1041-50. 2008
    ..We sought to determine clinical and biological risk factors for different IMIs during each period (early and late) after allogeneic HSCT...
  41. ncbi Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation
    Fulvio Crippa
    Fred Hutchinson Cancer Research Center, Seattle Washington 98109-1024, USA
    Biol Blood Marrow Transplant 8:281-9. 2002
    ..Because the risk for infections approaches that seen in allogeneic transplant recipients, infection surveillance, diagnostic work-up, and prevention strategies similar to those used in allogeneic recipients are warranted...
  42. ncbi Aspergillus galactomannan index: a surrogate end point to assess outcome of therapy?
    Kieren A Marr
    Clin Infect Dis 46:1423-5. 2008
  43. ncbi Plasminogen alleles influence susceptibility to invasive aspergillosis
    Aimee K Zaas
    Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS Genet 4:e1000101. 2008
    ..Furthermore, we demonstrated that plasminogen directly binds to Aspergillus fumigatus. We propose that genetic variation within the plasminogen pathway influences the pathogenesis of this invasive fungal infection...
  44. ncbi Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus
    S Arunmozhi Balajee
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
    Eukaryot Cell 4:625-32. 2005
    ..fumigatus and is not able to survive at 48 degrees C. Our findings suggest the presence of a previously unrecognized, potentially drug-resistant Aspergillus species that we designate A. lentulus...
  45. ncbi Resistant Microascus cirrosus pneumonia can be treated with a combination of surgery, multiple anti-fungal agents and a growth factor
    Celalettin Ustun
    The Department of Internal Medicine, Section of Hematology Oncology, Medical College of Georgia, 1120 15th Street, BAA 5407, Augusta, GA 30912 3125, USA
    Mycopathologia 162:299-302. 2006
    ..The Microascus genus rarely causes invasive fungal infection in humans and can be very difficult to treat because of the resistance to available antifungal agents...
  46. ncbi GliZ, a transcriptional regulator of gliotoxin biosynthesis, contributes to Aspergillus fumigatus virulence
    Jin Woo Bok
    Department of Plant Pathology, University of Wisconsin Madison, 882 Russell Labs, 1630 Linden Drive, Madison, WI 53706, USA
    Infect Immun 74:6761-8. 2006
    ..This may indicate that several secondary metabolites are involved in A. fumigatus virulence...
  47. ncbi Aspergillosis: spectrum of disease, diagnosis, and treatment
    Penelope D Barnes
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Infect Dis Clin North Am 20:545-61, vi. 2006
    ..This article examines the range of infections caused by Aspergillus species, the challenges of diagnosis, and current treatment options...
  48. ncbi Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 48:1773-7. 2004
    ..The rapidity and regularity of the rising resistance indicated that C. glabrata is able to upregulate drug efflux without losing the ability to maintain colonization...
  49. ncbi New methods to assess susceptibilities of Aspergillus isolates to caspofungin
    Alexander Imhof
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Clin Microbiol 41:5683-8. 2003
    ..Agar dilution is simple and reproducible, and results were consistent with the results of more technically demanding techniques. This method may be appropriate for use in the clinical laboratory...
  50. ncbi Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center
    Takahiro Fukuda
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA
    Biol Blood Marrow Transplant 10:494-503. 2004
    ....
  51. ncbi Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance
    Kieren A Marr
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington 98109, USA
    J Infect Dis 190:641-9. 2004
    ..The 0.5 cutoff may allow for better performance as an early diagnostic test...
  52. ncbi Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases
    William J Steinbach
    Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    Clin Infect Dis 39:192-8. 2004
    ..29; 95% CI, 0.15-0.56). Voriconazole is likely to be a better treatment choice for A. terreus infection than is a polyene...
  53. ncbi Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants
    Kieren A Marr
    Program of Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 103:1527-33. 2004
    ..69). There was no difference in overall or fungal-free survival. Itraconazole appears to prevent IMI in the subset of patients who tolerate the drug; however, toxicities and poor tolerability limit its success as prophylactic therapy...
  54. ncbi Cyclophosphamide metabolism is affected by azole antifungals
    Kieren A Marr
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D3 100, Seattle, WA 98109, USA
    Blood 103:1557-9. 2004
    ..These data suggest that azole antifungals, through differential inhibition of hepatic cytochrome P-450 isoenzymes, affect CY metabolism and conditioning-related toxicities...
  55. ncbi Antifungal therapy for febrile neutropenia: issues in clinical trial design
    Kieren A Marr
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N D3 100, Seattle, WA 98119, USA
    Curr Opin Investig Drugs 5:202-7. 2004
    ..Here, issues in trial design will be reviewed to address the question: Can (and should) new antifungals be evaluated for treatment of fever during neutropenia?..
  56. ncbi Invasive Candida infections: the changing epidemiology
    Kieren A Marr
    University of Washington, School of Medicine, and Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Oncology (Williston Park) 18:9-14. 2004
    ..Increasing evidence underscores the need to carefully evaluate antifungal treatment options, according to both host and therapeutic risks for drug resistance...
  57. ncbi Emerging fungal diseases
    Marcio Nucci
    University Hospital, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
    Clin Infect Dis 41:521-6. 2005
    ....
  58. ncbi Design issues in studies evaluating diagnostic tests for aspergillosis
    Kieren A Marr
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
    Clin Infect Dis 41:S381-6. 2005
    ..The widespread availability of a standardized assay may now allow us to address the multiple sources of variability and bias via large, cooperative studies...
  59. ncbi Reproducibility of low galactomannan enzyme immunoassay index values tested in multiple laboratories
    Arlo Upton
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Clin Microbiol 43:4796-800. 2005
    ..However, changes in GMI levels when different kit lots are used, and single samples with low-positive (GMI of 0.5 to 0.7) indices, should be interpreted with caution...
  60. ncbi (1-->3) beta -D-glucan assay in the diagnosis of invasive fungal infections
    Arlo Upton
    Clin Infect Dis 42:1054-6; author reply 1056. 2006
  61. ncbi Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis
    David W Denning
    Education and Research Centre, Wythenshawe Hospital and University of Manchester, Academic Department of Medicine and Surgery, Southmoor Road, Manchester M23 9LT, UK
    J Infect 53:337-49. 2006
    ..This study evaluated the safety and efficacy of micafungin in patients with proven or probable invasive aspergillosis (IA)...
  62. ncbi Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study
    Christian Junghanss
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA
    Biol Blood Marrow Transplant 8:512-20. 2002
    ..This risk is an important consideration for the future development of preventive strategies...
  63. ncbi Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the Euro
    Rodrigo Martino
    Hematology Department of Sant Pau Hospital, Autonomous University of Barcelona, Spain
    Blood 108:2928-36. 2006
    ..001]). These findings may help in the interpretation and design of future studies on secondary prophylaxis of IA after an allo-HSCT...
  64. ncbi Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy
    Morgan Hakki
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
    Antimicrob Agents Chemother 50:2522-4. 2006
    ..Reduced microbial susceptibility to all three echinocandins (caspofungin, anidulafungin, and micafungin) was noted but was not associated with mutations in FKS1...
  65. ncbi Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals
    S Arunmozhi Balajee
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Antimicrob Agents Chemother 48:1197-203. 2004
    ..These data suggest the potential presence of a genetically unique, poorly sporulating variant of A. fumigatus that demonstrates decreased susceptibilities to several antifungals...

Research Grants8

  1. Antifungal Drug Resistance in Aspergillus
    Kieren Marr; Fiscal Year: 2004
    ..These two aims have been developed to take is closer to the overall goal of decreasing Aspergillus associated mortality by developing more effective, laboratory directed therapeutic strategies. ..
  2. Immune reconstitution to Aspergillus
    Kieren Marr; Fiscal Year: 2007
    ..This information will be valuable for development of strategies to prevent and treat fungal infections in immunocompromised people. ..
  3. BioRad Galactomannan EIA for Diagnosis of Aspergillosis
    Kieren Marr; Fiscal Year: 2007
    ..This project is enabled by the cooperative activities of FHCRC investigators, Bio-Rad Laboratories, and several multicenter networks supported by the CDC, NIAID, and NHLBI. ..
  4. Inflammatory Responses to Aspergillus Fumigatus
    Kieren Marr; Fiscal Year: 2007
    ..fumigatus is coordinated. As this organism is a model lung commensal and pathogen, knowledge generated from these studies will also increase our understanding of mechanisms of specificity of innate host defense. ..
  5. Genetic Diversity of A. fumigatus
    Kieren Marr; Fiscal Year: 2007
    ..and will develop a stringent molecular typing method that will enhance our knowledge of the biology and population structure of the fungal pathogen A. fumigatus. ..